Tepper's Mistake: Expert Believes Billionaire Sold Too Soon on UnitedHealth

Billionaire hedge fund manager David Tepper made headlines recently for selling his entire stake in UnitedHealth Group (UNH). The move has raised questions about whether he made a costly mistake. In an interview, a financial expert argued that Tepper's decision to sell UNH was likely driven by a desire to focus on artificial intelligence investments, rather than any concerns about the company's performance.

According to the expert, UnitedHealth is not sitting still and hoping costs fall. Instead, it is reshaping how care is delivered across its insurance arm and Optum pharmacy management services. The company has implemented measures such as drawing clear lines on GLP-1 drugs, covering them for diabetes and cardiovascular risk under tight medical necessity rules and restricting coverage for weight loss alone.

UnitedHealth is also attacking administrative costs, which are a major factor in the company's margins. It plans to invest about $1.5 to $1.6 billion in AI in 2026, including a generative AI platform aimed at automating claims and back office work. Optum Rx has already used AI to cut call center volume by 25%, trim prior authorization times from hours to less than 30 seconds, and reduce denials and appeals by large double-digit percentages.

The company's latest results hint at a shift in its business model. Operating margin rose from 4.6% to 7.1% year over year, aided by a lower medical care ratio and improved cost management. Membership remains strong, and the mix continues to tilt toward Optum services, which carry higher margins than pure insurance.

The expert argues that UnitedHealth is adapting to a changing healthcare landscape, rather than falling behind. The company's scale and data give it an advantage over smaller players in the industry. While GLP-1 drugs will remain a challenge, they also reduce complications from diabetes and cardiovascular disease, which can lower hospital costs borne by insurers.